For Immediate Release
Chicago, IL – April 16, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Netflix, Inc. NFLX, PepsiCo, Inc. PEP, Novo Nordisk A/S NVO, Hawthorn Bancshares, Inc. HWBK and Park Aerospace Corp. PKE.
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Netflix, PepsiCo & Novo Nordisk
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Netflix, Inc., PepsiCo, Inc. and Novo Nordisk A/S, as well as two micro-cap stocks, Hawthorn Bancshares, Inc. and Park Aerospace Corp. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Today's Featured Research Reports
Netflix’s shares have underperformed the Zacks Broadcast Radio and Television industry over the past year (+10.5% vs. +19.3%). Per the Zacks analyst, concerns include uncertainty following the Warner Bros. Discovery non-deal and investor skepticism. High debt and heavy content obligations add leverage risk, while rising competition from Disney and Amazon could slow subscriber growth.
However, strengths include a growing subscriber base driven by localized and foreign-language content, strong engagement, and solid retention. Its diversified strategy spanning international programming, live events, and gaming supports long-term expansion ambitions.
(You can read the full research report on Netflix here >>>)
PepsiCo’s shares have outperformed the Beverages - Soft Drinks industry over the past year (+11.2% vs. +6.3%). The Zacks analyst believes that the company shows strong momentum, supported by resilient international growth, steady innovation and disciplined execution. Its global segment drives broad demand, while North America beverages benefit from share gains and new offerings. Productivity, automation and digital initiatives are improving efficiency and margins.
Yet, challenges include operational issues in its PFNA segment and ongoing cost and tariff pressures, which could weigh on near-term performance.
(You can read the full research report on PepsiCo here >>>)
Novo Nordisk’s shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past two years (-68.1% vs. +8.2%). The Zacks analyst believes that the company faces softer near-term momentum amid rising competition, pricing pressure and higher spending. Its outlook signals slower growth, and the stock has lagged the industry, tempering expectations of a quick turnaround.
However, growth is supported by strong demand for semaglutide drugs across obesity and diabetes. Label expansions, new approvals in Europe and the United States, and investments to boost production strengthen its long-term outlook.
(You can read the full research report on Novo Nordisk here >>>)
Hawthorn’s shares have outperformed the Zacks Banks - Northeast industry over the past two years (+71.2% vs. +51.9%). The Zacks analyst believes that the company’s outlook is supported by improving profitability from better asset yields, lower funding costs and steady loan growth, with solid credit quality. Strong capital enables dividends, selective buybacks and book value growth, while wealth management provides additional fee income.
Yet, risks include potential commercial credit stress, provisioning swings and reliance on wholesale funding. Elevated rates may limit flexibility, while expense growth and micro-cap sensitivity could increase volatility if margins peak.
(You can read the full research report on Hawthorn here >>>)
Park Aerospace’s shares have outperformed the Zacks Aerospace – Defense Equipment industry over the past year (+146.5% vs. +39.9%). The Zacks analyst believes that the company benefits from a long dividend track record and strong positioning in aerospace composites, supplying key materials for advanced aircraft. Its niche in complex components supports margins, while defense exposure and opportunities in fleet renewals, emerging markets and space add stability and growth.
However, risks include military program softness, customer delays, high input costs, customer concentration and geopolitical uncertainty, which may pressure near-term performance.
(You can read the full research report on Park Aerospace here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Zacks' Research Chief Picks Stock Most Likely to "At Least Double"
Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.
See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novo Nordisk A/S (NVO): Free Stock Analysis Report
Netflix, Inc. (NFLX): Free Stock Analysis Report
PepsiCo, Inc. (PEP): Free Stock Analysis Report
Park Aerospace Corp. (PKE): Free Stock Analysis Report
Hawthorn Bancshares, Inc. (HWBK): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).